A representative study by Roex et al. demonstrated that dual BCMA/CD19 CAR-NK cells effectively lysed tumor B-cell lines and primary patients samples while maintaining selective recognition of malignant cells, even at low effector to target ratios [131]. Here, CD19 is linked to neoplasm.